Related Experiment Video
Updated: May 29, 2026
Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
Published on: May 13, 2021
Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains
Jean-Simon Diallo1, Markus Vähä-Koskela, Fabrice Le Boeuf
1Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada.
Abstract:
Oncolytic viruses are self-amplifying therapeutics that specifically replicate in and kill cancer cells. We have previously shown that vesicular stomatitis virus (VSV) can be used as an oncolytic virus. A strain of VSV harboring a mutation in the M protein (VSVΔ51) was found to exhibit enhanced tumor selectivity over its wild-type counterpart due to its inability to overcome antiviral programs in normal cells and due to the frequent defects in antiviral signaling pathways observed in the majority of tumors. VSVΔ51 can harbor transgenes, is easily propagated and purified to high titers, and shows potent oncolytic activity in several mouse models, including syngeneic CT26-lacZ subcutaneous colon carcinoma models. However, VSV-neutralizing antibodies targeting mainly the VSV-G surface glycoprotein arise within 3-5 days following the initial dose. This should be considered for strategies aiming at increasing the effectiveness of VSV through delivery of additional doses of virus or aiming to prolong VSV replication in vivo.
Insights
Vesicular stomatitis virus (VSVΔ51) shows promise as an oncolytic virus, selectively killing cancer cells. However, the development of VSV-neutralizing antibodies limits its effectiveness for repeated or prolonged treatments.
Area of Science:
- Oncolytic virotherapy
- Virology
- Cancer research
Background:
- Oncolytic viruses are engineered viruses that selectively replicate in and destroy cancer cells.
- Vesicular stomatitis virus (VSV) has demonstrated potential as an oncolytic agent.
- A specific strain, VSVΔ51, exhibits enhanced tumor selectivity due to impaired replication in normal cells and defects in tumor antiviral pathways.
Purpose of the Study:
- To evaluate the oncolytic potential and characteristics of the VSVΔ51 strain.
- To assess the efficacy of VSVΔ51 in preclinical cancer models.
- To identify limitations for therapeutic application, particularly regarding host immune response.
Main Methods:
- Utilized a mutated strain of vesicular stomatitis virus (VSVΔ51) with enhanced tumor selectivity.
- Tested VSVΔ51 in syngeneic CT26-lacZ subcutaneous colon carcinoma mouse models.
- Monitored the development of VSV-neutralizing antibodies post-administration.
Main Results:
- VSVΔ51 demonstrated potent oncolytic activity in preclinical models.
- The virus showed enhanced tumor selectivity compared to wild-type VSV.
- VSV-neutralizing antibodies targeting the VSV-G surface glycoprotein emerged within 3-5 days, indicating a potential limitation for repeated dosing.
Conclusions:
- VSVΔ51 is a potent oncolytic virus with improved tumor selectivity.
- The rapid emergence of neutralizing antibodies against VSV-G is a critical factor to consider for therapeutic strategies.
- Further research is needed to overcome antibody-mediated neutralization for sustained therapeutic efficacy.
